Leerink Partners Maintains Outperform on Sarepta Therapeutics, Raises Price Target to $230
Portfolio Pulse from Benzinga Newsdesk
Leerink Partners maintains an Outperform rating on Sarepta Therapeutics (NASDAQ:SRPT) and raises the price target from $165 to $230.
June 24, 2024 | 11:19 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Leerink Partners has maintained its Outperform rating on Sarepta Therapeutics and raised the price target from $165 to $230, indicating strong confidence in the company's future performance.
The raised price target from $165 to $230 by Leerink Partners suggests a significant upside potential for Sarepta Therapeutics. The Outperform rating indicates strong confidence in the company's future performance, likely leading to positive investor sentiment and a potential increase in stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100